Please use this identifier to cite or link to this item:
|Title:||Inhibition of peptidases in the control of blood pressure.|
|Authors:||Kubota, Eiji;Dean, Rachel G;Balding, Leanne C;Burrell, Louise M|
|Affiliation:||Department of Medicine, University of Melbourne, Austin, Australia.|
|Citation:||Essays in Biochemistry; 38(): 129-39|
|Abstract:||The natriuretic peptide and renin-angiotensin systems are physiological counterparts with opposite roles in the regulation of electrolyte balance and blood pressure. In both systems, membrane-bound, zinc-dependent peptidases play an important role in the inactivation or activation of the system. Angiotensin-converting enzyme (ACE) converts angiotensin I into angiotensin II, and neutral endopeptidase (NEP) degrades the natriuretic peptides. Simultaneous inhibition NEP and ACE by a single molecule (a vasopeptidase inhibitor) is a new therapeutic approach in hypertension. Wider applications for vasopeptidase inhibitors being studied include their role as cardioprotective agents in heart failure, as renoprotective agents in chronic renal failure and diabetic nephropathy, and as vasculoprotective agents in endothelial dysfunction and athersclerosis.|
|Internal ID Number:||12463166|
Atrial Natriuretic Factor.chemistry
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.